Streetbeat News

Products Services

NOW

Bell Canada and ServiceNow have announced an expanded multi-year strategic agreement to support Bell's digital transformation and enhance its tech services portfolio for enterprise customers. Bell will leverage the ServiceNow platform to streamline various business-critical areas.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:18 pm

EVLV

Evolv Technology (NASDAQ: EVLV) has partnered with 360 CHICAGO to enhance guest experience by installing its AI-based screening system, Evolv Express®, at the observation deck. This upgrade replaces manual bag checks and is part of recent renovations.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:16 pm

TWST

Twist Bioscience Corporation (NASDAQ:TWST) announced the dosing of the first patient in Pure Biologics' exploratory Phase 0 clinical study of PBA-0405, an antibody discovered using Twist's antibody libraries. This study aims to evaluate the pharmacodynamic activity of PBA-0405 in solid tumors.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:15 pm

RDY

TAK

Dr. Reddy's Laboratories has signed a non-exclusive patent licensing agreement with Takeda Pharmaceutical to commercialize Vonoprazan in India.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:14 pm

NKGN

NKGen Biotech will present new biomarker data on SNK01, an autologous non-genetically modified NK cell therapy, at the Alzheimer's Association International Conference. The data will focus on SNK01's ability to reduce α-synuclein in Alzheimer's patients, which is linked to cognitive function.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:13 pm

META

Meta Platforms Inc. is considering a multibillion-dollar investment in EssilorLuxottica, the maker of Ray-Ban, to expand their smart glasses partnership.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:13 pm

CLDI

Calidi Biotherapeutics (NYSE:CLDI) has received a new U.S. patent for its SuperNova technology platform, enhancing its intellectual property and advancing its CLD-201 program.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:12 pm

META

METD

METU

Meta Platforms Inc (NASDAQ:META) faces mixed sentiments as Wolfe Research gives it an Outperform rating with a $620 price target, while concerns about its ad business and earnings surprises persist. Direxion's METU and METD ETFs allow traders to leverage or inverse trade META stock, with recent market volatility impacting their performance.

Portfolio Pulse from Joshenomoto@benzinga.com

July 18, 2024 | 12:11 pm

PHAT

The FDA has approved Phathom Pharmaceuticals' Voquezna (Vonoprazan) 10 mg tablets for treating heartburn associated with non-erosive gastroesophageal reflux disease in adults. This marks the third FDA approval for Voquezna.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:10 pm

GENI

X and Genius Sports have launched the Trend Genius product, which uses real-time conversations to optimize ad spend during major summer sporting events. This new technology aims to maximize ad engagement by running campaigns during peak conversation times and pausing them when engagement slows.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:09 pm